-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
News on October 12th, CDMO, a CDMO company focusing on small molecule innovative drugs, completed a round C financing of nearly 500 million yuan, led by Yingke Capital, October Capital, Jiangsu Huarui, China Industrial Securities Innovation, Coupled Fund, Yueshi Investment, Zhongcheng New Industries, and Pingtan Yihe followed in the investment, and the old shareholder Huayi Capital continued to pursue investment
.
This round of financing will be mainly used for the construction of the Cangzhou subsidiary's CDMO base project, Hefei new drug research and development and GMP production base construction, and the construction of Shanghai Innovation Accelerator Laboratory
.
According to data, Rovi Pharmaceuticals specializes in Innovative Medicine Industrialization Outsourcing Services (CDMO)
.
The scope of services covers the chemical-related links of innovative medicine from laboratory to industrialization process development and transformation, including process research, process development, process optimization, pilot test and industrial production services from pre-clinical to marketed drugs, etc.
The therapeutic field involves anti-viral, anti-tumor, cardiovascular system diseases, metabolic diseases, central nervous system
.
It has deployed R&D centers and production bases at home and abroad, and established overseas business centers.
Currently, it serves hundreds of R&D and production project orders each year
.
Pharmaceutical CDMO is an emerging R&D and production outsourcing model
.
In recent years, with the acceleration of the review and approval of new drugs and the advancement of the consistency evaluation of generic drugs, China's drug innovation has been continuously upgraded, and the innovative drug market has developed rapidly, which has driven the growth of demand in the CDMO industry
.
Coupled with the accelerated transfer of overseas production capacity, the domestic CDMO industry has ushered in a period of prosperity
.
According to Frost & Sullivan data, the compound growth rate of the domestic CDMO industry from 2019 to 2021 is nearly 20%, which is higher than the 12% growth rate overseas in the same period
.
Industry insiders predict that by 2024, the market size of China's CDMO industry will grow to 104.
88 billion yuan, and the corresponding growth rate from 2019 to 2024 will reach 26.
5%
.
In the context of the rapid growth of the CDMO industry, the market continues to increase, and new entrants continue to join in.
At the same time, capital is also able to provide professional, efficient, cost-effective services and strong competitiveness for Chinese biomedical companies with years of accumulated experience.
, Pay attention to potential companies
.
It is understood that Rovi Pharmaceuticals was listed on the New Third Board in 2016 and received 100 million yuan in Series B financing in 2018 for the construction of a one-stop service platform for small molecule innovative drug production process research and development, process optimization, pilot and large-scale production.
; In August 2019, nearly 100 million yuan of B+ round of financing was completed for the construction of technology research and development and business operation teams
.
It can be seen that the capital market is more optimistic about the company, and after receiving a new round of financing, Levi Pharmaceuticals will promote the construction of GMP bases and better provide customers with high-efficiency services
.
In addition to Rovi Pharmaceuticals, a number of biomedical CDMO companies have received RMB 100 million in financing this year
.
For example, in August of this year, Huaxian Pharmaceutical received 150 million yuan in round B financing, which is mainly used for the construction and operation of the second phase of the Huizhou Daya Bay GMP factory project, accelerating the deployment of downstream independent capacity construction, and starting the construction of the East China R&D center to provide better services Customer
.
In May, the company also received RMB 100 million in Series A financing for the construction of Huaxian Pharmaceutical’s medicinal chemistry CRO business research and development platform and Raffles’ CDMO business GMP production base; in March, the CDMO and media biotechnology company "Auskang Biotech "Pharmaceuticals" announced the completion of a series C financing of more than 400 million yuan, which will be used to expand the production capacity of the CDMO business and culture medium business; another example, in February this year, Beino announced the completion of nearly 100 million yuan of Pre-A round of financing for Baidu Inno's R&D and production base construction and talent introduction in Taicang, Suzhou
.
.
This round of financing will be mainly used for the construction of the Cangzhou subsidiary's CDMO base project, Hefei new drug research and development and GMP production base construction, and the construction of Shanghai Innovation Accelerator Laboratory
.
According to data, Rovi Pharmaceuticals specializes in Innovative Medicine Industrialization Outsourcing Services (CDMO)
.
The scope of services covers the chemical-related links of innovative medicine from laboratory to industrialization process development and transformation, including process research, process development, process optimization, pilot test and industrial production services from pre-clinical to marketed drugs, etc.
The therapeutic field involves anti-viral, anti-tumor, cardiovascular system diseases, metabolic diseases, central nervous system
.
It has deployed R&D centers and production bases at home and abroad, and established overseas business centers.
Currently, it serves hundreds of R&D and production project orders each year
.
Pharmaceutical CDMO is an emerging R&D and production outsourcing model
.
In recent years, with the acceleration of the review and approval of new drugs and the advancement of the consistency evaluation of generic drugs, China's drug innovation has been continuously upgraded, and the innovative drug market has developed rapidly, which has driven the growth of demand in the CDMO industry
.
Coupled with the accelerated transfer of overseas production capacity, the domestic CDMO industry has ushered in a period of prosperity
.
According to Frost & Sullivan data, the compound growth rate of the domestic CDMO industry from 2019 to 2021 is nearly 20%, which is higher than the 12% growth rate overseas in the same period
.
Industry insiders predict that by 2024, the market size of China's CDMO industry will grow to 104.
88 billion yuan, and the corresponding growth rate from 2019 to 2024 will reach 26.
5%
.
In the context of the rapid growth of the CDMO industry, the market continues to increase, and new entrants continue to join in.
At the same time, capital is also able to provide professional, efficient, cost-effective services and strong competitiveness for Chinese biomedical companies with years of accumulated experience.
, Pay attention to potential companies
.
It is understood that Rovi Pharmaceuticals was listed on the New Third Board in 2016 and received 100 million yuan in Series B financing in 2018 for the construction of a one-stop service platform for small molecule innovative drug production process research and development, process optimization, pilot and large-scale production.
; In August 2019, nearly 100 million yuan of B+ round of financing was completed for the construction of technology research and development and business operation teams
.
It can be seen that the capital market is more optimistic about the company, and after receiving a new round of financing, Levi Pharmaceuticals will promote the construction of GMP bases and better provide customers with high-efficiency services
.
In addition to Rovi Pharmaceuticals, a number of biomedical CDMO companies have received RMB 100 million in financing this year
.
For example, in August of this year, Huaxian Pharmaceutical received 150 million yuan in round B financing, which is mainly used for the construction and operation of the second phase of the Huizhou Daya Bay GMP factory project, accelerating the deployment of downstream independent capacity construction, and starting the construction of the East China R&D center to provide better services Customer
.
In May, the company also received RMB 100 million in Series A financing for the construction of Huaxian Pharmaceutical’s medicinal chemistry CRO business research and development platform and Raffles’ CDMO business GMP production base; in March, the CDMO and media biotechnology company "Auskang Biotech "Pharmaceuticals" announced the completion of a series C financing of more than 400 million yuan, which will be used to expand the production capacity of the CDMO business and culture medium business; another example, in February this year, Beino announced the completion of nearly 100 million yuan of Pre-A round of financing for Baidu Inno's R&D and production base construction and talent introduction in Taicang, Suzhou
.
